- Home
- Managing expenses
- Schemes and subsidies
- MediShield Life
- Cancer Drug List
Cancer Drug List
The Cancer Drug List below shows the outpatient cancer treatments that are claimable and the corresponding MSHL and MSV limits.
Last updated 20 December 2024
In August 2021, MOH announced changes to the financing of outpatient cancer treatment to help ensure the cost of cancer treatments and insurance premiums remain affordable over time.
The changes to MediShield Life (MSHL) and Medisave (MSV) were implemented on 1 September 2022, while the change to Integrated Shield Plans (IPs) will take effect from 1 April 2023, upon policy purchase or renewal. More details can be found by using this link. An overview of the cancer financing changes can be found in this brochure [PDF, 1.2MB].
The Cancer Drug List below shows the outpatient cancer treatments that are claimable and the corresponding MSHL and MSV limits. IP claim limits are set by the private insurers. The subsidy classes in the CDL apply to drugs at public healthcare institutions. Drugs can be subsidised under the Standard Drug List (SDL) or Medication Assistance Fund (MAF).
Please click here for a list of FAQs on Cancer Treatment Financing.
Cancer Drug List
The subsidy class, and MediShield Life and MediSave limits may change from time to time. The prevailing subsidy class, and MediShield Life and MediSave limits will be applied at the point the patient receives treatment. Brands specified in the 'subsidy class' column refers to the eligibility for SDL subsidy only. Other brand(s) of the same active ingredient, while not eligible for SDL subsidy, will follow the same MediShield Life (MSHL), MediSave and IP coverage.
Explanatory note on category
Refers to the MediShield Life claim limit tiers, as prescribed in the Sixth Schedule of the MediShield Life Scheme Regulations 2015. In relation to the First Schedule of the Central Provident Fund (Medisave Account Withdrawals) Regulations, categories 1 to 27 are considered the “first tier” of the CDL, while categories 28 to 48 are considered the “second tier” of the CDL.
MediShield Life Claim Limit per month for each category
Category | MediShield Life Claim Limit per month ($) |
1 | $200.00 |
2 | $400.00 |
3 | $600.00 |
4 | $800.00 |
5 | $1,000.00 |
6 | $1,200.00 |
7 | $1,400.00 |
8 | $1,600.00 |
9 | $1,800.00 |
10 | $2,000.00 |
12 | $2,400.00 |
15 | $3,000.00 |
16 | $3,200.00 |
19 | $3,800.00 |
26 | $5,200.00 |
27 | $5,400.00 |
46 | $9,200.00 |
48 | $9,600.00 |
Updated 1 November 2024.
Search the list
Cancer type | Active ingredient(s) | Dosage Form(s) and Strength(s) | Brand(s) | Clinical indications | Subsidy Status | MediShield Life Claim Limit per month ($) | MediSave Withdrawal Limit per month ($) | Category |
|---|---|---|---|---|---|---|---|---|
Breast cancer | Abemaciclib | Abemaciclib tablet (50 mg, 100 mg, 150 mg) | - | Abemaciclib in combination with endocrine therapy for adjuvant treatment of patients with HR positive, HER2 negative, node-positive early breast cancer at high risk of recurrence. Maximum treatment duration: 2 years. | MAF | $ 800 | $ 600 | 4 |
Breast cancer | Abemaciclib | Abemaciclib tablet (50 mg, 100 mg, 150 mg) | - | Abemaciclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer. | MAF | $ 800 | $ 600 | 4 |
Breast cancer | Abemaciclib | Abemaciclib tablet (50 mg, 100 mg, 150 mg) | - | Abemaciclib in combination with fulvestrant for treating HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy. | MAF | $ 800 | $ 600 | 4 |
Others | Abiraterone | Abiraterone tablet (500 mg, 1000 mg) | - | For cancer treatment. | No subsidy | $ 400 | $ 600 | 2 |
Others | Abiraterone | Abiraterone tablet (250 mg) | - | For cancer treatment. | SDL | $ 400 | $ 600 | 2 |
Leukaemia | Acalabrutinib | Acalabrutinib capsule (100 mg) and tablet (100 mg) | Calquence | Monotherapy for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy. | MAF | $ 2,000 | $ 600 | 10 |
Leukaemia | Acalabrutinib | Acalabrutinib capsule (100 mg) and tablet (100 mg) | Calquence | Monotherapy for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy. | MAF | $ 2,000 | $ 600 | 10 |
Lymphoma | Acalabrutinib | Acalabrutinib capsule (100 mg) and tablet (100 mg) | Calquence | Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. | MAF | $ 2,000 | $ 600 | 10 |
Leukaemia | Acalabrutinib plus obinutuzumab | Acalabrutinib capsule (100 mg) and tablet (100 mg) | Calquence | Acalabrutinib in combination with obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy. | No subsidy | $ 3,000 | $ 600 | 15 |
Lung cancer | Afatinib | Afatinib tablet (20 mg, 30 mg, 40 mg) | Giotrif | Treatment of locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer. | MAF | $ 600 | $ 600 | 3 |